NCT07265271 Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)
| NCT ID | NCT07265271 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Hepatocellular Carcinoma (HCC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-01-15 |
| Primary Completion | 2028-06-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2025-01-15 with a primary completion date of 2028-06-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a multi-omics-based liquid biopsy assay, especially focusing on ncRNAs (e.g. tsRNA, miRNA, circRNA, lncRNA, etc.) for accurate detection of early-stage HCC.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 100 years. * A histologically confirmed diagnosis of hepatocellular carcinoma. * A clinically diagnosed as chronic liver disease, including chronic hepatitis or liver cirrhosis, without evidence of hepatocellular carcinoma. * Healthy volunteers without known liver disease or malignancy. * Received standard diagnostic and staging procedures as per local guidelines * Availability of blood or other biospecimens. * Ability to provide written informed consent. Exclusion Criteria: * Lack of or inability to provide informed consent * History of other active malignancies within the past 5 years * Previous liver transplantation * Severe systemic infection or inflammatory disease at the time of enrollment * Inadequate sample quality or quantity
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07265271 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma (HCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07265271 currently recruiting?
Yes, NCT07265271 is actively recruiting participants. Contact the research team at ajgoel@coh.org for enrollment information.
Where is the NCT07265271 trial being conducted?
This trial is being conducted at Duarte, United States.
Who is sponsoring the NCT07265271 clinical trial?
NCT07265271 is sponsored by City of Hope Medical Center. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.